BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals. We also represent state and regional biotech associations, service providers to the industry, and academic centers. Our members help foster a healthy economy by creating good-paying, biotechnology jobs. We also host the largest cost-savings program in the life sciences industry, BIO Business Solutions, which saved $430 million in aggregate for 3,700+ companies last year.
BIO also works towards enriching the industry with networking, partnering and education opportunities. We organize the BIO International Convention, the global event for biotechnology, along with many other industry-leading investor and partnering events held around the world. Arguably the industry’s leading partnering software, BIO One-on-One Partnering™ facilitates 50,000 face-to-face meetings each year among investors, biotechs, pharmaceutical companies, academic institutions and non-profits at live events.
To advocate for our industry, BIO is organized into four different sections to best represent our members and their goals:
We serve the needs of small-to-medium size companies, most of whom do not yet have major products approved and on the market. Whether advocating for pro-innovation tax policies to encouraging an economic and policy environment to foster biotech investment, we focus on critical issues affecting smaller companies and build programs to enhance their development.
We promote biomedical innovation by developing and advocating for public policies that represent the best interests of members focused on human health. We break-down the barriers that impede American innovation by reducing bureaucratic hurdles to lifesaving technologies. Among the priority issues are matters affecting the healthcare-related regulatory and reimbursement climate, pandemic and biodefense preparedness, publicly funded scientific research, and personalized medicine.
We promote the use of industrial enzymes, conversion of biomass to energy and chemicals, and innovative clean up technologies. We work closely with the U.S. Congress, federal agencies, and international organizations to encourage the development of technologies that make our lives and environment cleaner, safer and healthier.
We create and advance industry policies on all food and agriculture biotechnology issues related to international affairs, government relations, science and regulatory affairs, and media and public affairs. We work for a safe and clean supply of healthy food for a growing global population.